2013 revenue of China Resources Pharmaceutical Co., Ltd. has been promoted to 100 billion yuan. There is no timetable for its overall listing

Source: First Financial Daily on January 9, 2014, following Sinopharm group, China Resources Pharmaceutical Group also promoted to the 100 billion club in 2013, becoming the second largest pharmaceutical group in China Yesterday, Wei bin, the chief accountant of China Resources Group (Co., Ltd.), revealed in an exclusive interview with the media that in 2013, the turnover and total assets of China Resources Pharmaceutical Co., Ltd exceeded 100 billion yuan, with a net profit between 5 billion and 6 billion yuan, becoming the second largest turnover industry of China Resources Group Wei bin told reporters that in 2013, the revenue of China Resources medical sector was 116 billion yuan, with a growth rate of more than 30% It is the industry sector with the fastest growth and the highest return rate among the seven major industries of China Resources On October 22, 2013, China Resources Pharmaceutical Group announced the official launch of "China Resources pharmaceutical Beijing Industrial Park" project construction in Beijing The project is one of the important contents of the cooperation framework agreement signed by CR pharma and Beijing Municipal Government four years ago when CR Pharma completed the acquisition of Beijing Pharma Group, and it is also an important measure for CR Pharma to march towards biopharmaceuticals In the current sector of China Resources pharmaceutical, the five business areas of pharmaceutical business, traditional Chinese medicine, health products, brand prescription drugs and medical devices completed through merger have their own strengths Wei bin told the media that according to the development strategy of Cr Pharma, the pharmaceutical assets will be integrated into five business platforms, including OTC (over-the-counter medicine) and traditional Chinese medicine with Cr Sanjiu as the main body, chemical and general medicine with Cr Shuanghe as the main body, medical equipment with Cr Wandong as the main body, health products with dong'a gum as the main body and pharmaceutical circulation with Cr Pharma business group as the main body "According to such a strategic plan, the OTC and traditional Chinese medicine business of China Resources pharmaceutical will be put into China Resources Sanjiu sooner or later, such as Zizhu pharmaceutical, chemical medicine into China Resources Shuanghe, such as SECCO pharmaceutical Zizhu Pharmaceutical Co., Ltd and Secco Pharmaceutical Co., Ltd are very high-quality enterprises with annual profits of 200 million yuan " Wei Bin said Last year, the restructuring of Beijing Zizhu Pharmaceutical Co., Ltd by CR 39 ran aground Wei bin revealed that the suspension was caused by "problems" in the internal management of Zizhu Pharmaceutical Co., Ltd According to our reporter, in order to improve the performance, Zizhu pharmaceutical industry has taken the way of increasing sales revenue by pressing products from channels If Zizhu is put into China Resources 39 immediately, it will be detrimental to the development of China Resources 39 Li fuzuo, chairman of China Resources Pharmaceutical Group, also mentioned in an interview with the media at the end of last year that the termination of the restructuring of Zizhu pharmaceutical industry by China Resources 39 Co., Ltd "is not a failure, but a grasp of the opportunity China Resources pharmaceutical will not push its assets to the market at will, and must follow a scientific attitude." In the commercial circulation sector, before that, compared with Sinopharm, the commercial circulation of China Resources pharmaceutical was a short board However, with a series of acquisitions, Cr Pharma is trying to change this situation According to Wei bin, the business revenue of China Resources pharmaceutical reached 70 billion yuan in 2013 "In the past few years, Cr Pharma has acquired more than 80 municipal pharmaceutical companies across the country Therefore, the focus of Cr Pharma's commercial circulation business now lies in the construction of provincial platforms Of course, in the blank area, we will continue to merge and acquire." However, as the internal restructuring has not yet been completed, there is still no timetable for the overall listing of China Resources pharmaceutical in Hong Kong "BeiYao group is still in the process of integration, and there is no timetable for the overall overseas listing of the pharmaceutical sector." Wei Bin said.